BioVie Inc. (BIVI): Price and Financial Metrics
BIVI Price/Volume Stats
Current price | $0.49 | 52-week high | $8.69 |
Prev. close | $0.50 | 52-week low | $0.45 |
Day low | $0.49 | Volume | 411,600 |
Day high | $0.51 | Avg. volume | 2,007,255 |
50-day MA | $0.67 | Dividend yield | N/A |
200-day MA | $2.26 | Market Cap | 19.58M |
BIVI Stock Price Chart Interactive Chart >
BioVie Inc. (BIVI) Company Bio
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.
Latest BIVI News From Around the Web
Below are the latest news stories about BIOVIE INC that investors may wish to consider to help them evaluate BIVI as an investment opportunity.
Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TVORLANDO, FL / ACCESSWIRE / December 22, 2023 / RedChip Companies will air interviews with Rail Vision (NASDAQ:RVSN) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December ... |
BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVieAvidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog. |
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & MoreRegulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week. |
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study DataBioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company. |
BIVI Price Returns
1-mo | 2.17% |
3-mo | -52.43% |
6-mo | -88.99% |
1-year | -94.00% |
3-year | -96.29% |
5-year | -96.39% |
YTD | -61.11% |
2023 | -83.78% |
2022 | 72.67% |
2021 | -74.02% |
2020 | 394.86% |
2019 | N/A |
Loading social stream, please wait...